Noval modalities, anti-bacterials, digitalization in healthcare industry, business strategy

As a Boston native, graduate of the now defunct Harvard-MIT Biomedical Enterprise Program at (MIT Sloan and HMS), co-founder of successfully commercialized device start-up and and now drug development, former international healthcare management consultant and now development and commercialization leader at Alnylam pharmaceuticals, my perspective reflects (1) broad experience in the path from bench to commercialized and highly innovative therapeutic (2) highly strategic perspective on the dynamics between academia, industry, payers and providers, and (3) deep passion for the Boston Life Science Ecosystem. Brief relevant experience includes: 2017 - Present: Alnylam Pharmaceuticals Global Market Access Lead -- globally responsible for pricing and reimbursement for pipeline of innovative RNAi therapeutic products 2014-2017: Alnylam Pharmaceuticals (Cambridge) Program Manager -- responsible for global development of novel RNAi-based therapeutic for pediatric orphan disease from discovery through proof-of-concept 2014-2017: Alnylam Pharmaceuticals (Cambridge) Head of Business Planning -- responsible for overseeing financial and operational strategic planning for company, growing from 200 to 800 employees, and up to $500M annual spend 2009 - 2014: McKinsey and Company (London) -- Senior Engagement Manager -- led strategic analyses and initiatives across all aspects of healthcare, including healthcare systems (payer and provider), biopharmaceutical development and commercialization, and global public health 2009: Co-founder, Momelan Therapeutics (Cambridge) developing and commercializing technology from MGH Wellman Center, angel and venture backed 2007-2009: MBA and SM, Harvard-MIT Biomedical Enterprise Program (Cambridge) Small and highly selective joint 3-year program administered by MIT Sloan School of Management and Harvard-MIT Division of Health Sciences and Technology 2003-2006: Legislative Assistant (Washington DC): US Congressman Jim Cooper, representing Nashville Tennessee in US Congress, covering Intellectual Property, Healthcare and other policy areas Finally, it's worth noting that my inspiration for entering healthcare and biotech was actually a 1995 seminar for public high school students by Dr Francis Collins, hosted at the Whitehead Institute, in which his main message was "we need people who can span the gap between science and the broader society". That is the role I've sought to play ever since.

I’ve worked in HIT in MA, in the US, and globally for over a dozen years and worked in health services research and Health policy for the US Congress for 10 years before that. I now facilitate a Digital Health Care Forum at a Global standards development organization (SDO) with participants from all major sectors of the HC enterprise. I did work for the Mass Technology Collaborative’s FAST program in the late 2000’s.

I am leading the R&D department at Corindus Vascular Robotics, with the focus on robotics in medicine. Our current focus is to increase the access to quality care through robotics, enabled by remote connectivity for tele-proctoring and tele-treatment.

I have extensive sales/sales leadership experience in Biopharma and how biopharma works together with Payers / Health Plans, Academic Medical Centers and Research Institutes, Regulators and Advocacy Groups / Associations.